Antibody Peptides as Cancer Vaccine-Turning Weapons to Targets.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33268550.
- Also identified by DOI 10.1158/1078-0432.CCR-20-3977.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Stereotyped B-cell receptors (BCR) are frequent in patients with chronic lymphocytic leukemia (CLL). In cell culture and in mouse models of CLL, immunogenic epitopes of these BCRs were shown to trigger specific T-cell responses and to control leukemia development. These results suggest vaccination with autologous BCR-derived peptides as a novel therapy for CLL.<i>See related article by Rovida et al., p. 729</i>.
Medical subject headings
- Cancer Vaccines
- Leukemia, Lymphocytic, Chronic, B-Cell